Paragon CareFRA:PXS -6.99%56 EBITDA Margin % is -0.02% as of Dec. 2025. GuruFocus rates FRA:PXS with a GF Score™ of 56/100 and a GF Value™ of €0.20 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 117 Medical Distribution companies, Paragon Care ranks worse than 82.05% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Paragon Care's EBITDA for the
six
months ended in Dec. 2025 was €-0 Mil. Paragon Care's Revenue for the
six
months ended in Dec. 2025 was €1,081 Mil. Therefore, Paragon Care's EBITDA margin for the quarter that ended in Dec. 2025 was -0.02%.
Paragon Care (FRA:PXS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Paragon Care EBITDA Margin % Related Terms
Paragon Care EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Paragon Care's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PXS vs MCK, CAH, COR: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Paragon Care's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paragon Care EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Paragon Care's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Paragon Care's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paragon Care (FRA:PXS) has a EBITDA Margin % of -0.02% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Paragon Care and its competitors. According to the industry distribution chart, Paragon Care ranks #96 out of 117 companies in the Medical Distribution industry, placing it in the top 82.1%.
Is Paragon Care's EBITDA Margin % too high?
Paragon Care's current EBITDA Margin % is -0.02%. Based on the distribution chart, Paragon Care ranks #96 out of 117 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Paragon Care has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Paragon Care's EBITDA Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Paragon Care ranks #96 out of 117 companies for EBITDA Margin %. This places Paragon Care in the lower half of its industry. The industry median EBITDA Margin % is 4.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.28, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Paragon Care and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paragon Care's current EBITDA Margin % is -0.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paragon Care stock overvalued right now?
Based on GuruFocus' analysis, Paragon Care (FRA:PXS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.20, compared to a current price of €0.07 — trading 66.8% below its estimated fair value. The current EBITDA Margin % is -0.02%. Paragon Care's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Paragon Care (FRA:PXS), the current EBITDA Margin % is -0.02% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paragon Care (FRA:PXS) Overvalued in 2026?
Based on GuruFocus' analysis, Paragon Care stock appears to be undervalued.
The current stock price of €0.07 is trading 66.8% below its estimated GF Value™ of €0.20.
GuruFocus considers Paragon Care to be Possible Value Trap.
Key valuation signals for FRA:PXS:
EBITDA Margin %: -0.02%
GF Value™: €0.20 vs. price of €0.07 (66.8% below fair value)
No single metric tells the full story. See the FRA:PXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paragon Care Ltd is a medical device company. The company provides medical equipment, devices, and consumables medical products to the healthcare market. The company provides solutions to various healthcare markets, aged care, and veterinary markets. The group is organized into two operating segments: ParagonCare and CH2 Holdings and the majority of its revenues are generated from the CH2 Holdings segment engaged in the distribution of pharmaceuticals, medical consumables, nutritional, and over-the-counter products to the healthcare market.
56GF Score
Get the complete analysis for FRA:PXS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PXS has been successfully added to your 
